

Consolidated Financial Statements

June 30, 2022 and 2021

(With Independent Auditors' Report Thereon)

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Balance Sheets	3
Statements of Operations	4
Statements of Changes in Net Assets	5
Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7–36



KPMG LLP 1201 Demonbreun Street Suite 1100 Nashville, TN 37203

Independent Auditors' Report

The Board of Directors Arkansas Children's:

Opinion

We have audited the consolidated financial statements of Arkansas Children's, which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of Arkansas Children's as of June 30, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of Arkansas Children's and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Arkansas Children's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
 financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Arkansas Children's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Arkansas Children's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

KPMG LLP

Memphis, Tennessee October 27, 2022

Consolidated Balance Sheets

June 30, 2022 and 2021

Assets	2022	2021
Current assets:		
Cash and cash equivalents	\$ 86,554,668	93,916,413
Net patient accounts receivable	106,800,778	82,554,373
Other current receivables	36,783,354	35,928,040
Investments – at fair value	534,366,311	518,249,823
Assets limited as to use – current	5,029,175	4,652,525
Estimated third-party payor settlements – current	131,439,770	138,050,512
Inventories	12,039,917	10,809,276
Prepaids and other current assets	13,203,131	12,654,727
Total current assets	926,217,104	896,815,689
Assets limited as to use – noncurrent	393,010,225	414,592,496
Pledges receivable – noncurrent	18,330,446	21,109,761
Property, plant, and equipment – net	388,482,314	411,127,876
Operating right of use assets, net	10,320,871	3,287,080
Other noncurrent assets	81,807,300	61,328,774
Total assets	\$ <u>1,818,168,260</u>	1,808,261,676
Liabilities and Net Assets		
Current liabilities:		
Accounts payable	\$ 44,716,550	47,120,968
Accrued interest	2,124,175	2,167,525
Accrued expenses and other liabilities	68,791,970	55,583,902
Operating leases – current	2,000,498	1,361,065
Current portion of long-term debt	4,807,611	4,351,338
Total current liabilities	122,440,804	110,584,798
Noncurrent liabilities:		
Other long-term payables	2,363,414	5,503,737
Operating leases – noncurrent	8,320,373	1,926,015
Grant carryover	8,644,402	9,368,401
Long-term debt – net of current portion	153,726,223	158,884,691
Total liabilities	295,495,216	286,267,642
Commitments and contingencies		
Net assets:		
Without donor restrictions	1,319,429,805	1,316,644,127
With donor restrictions	203,243,239	205,349,907
Total net assets	1,522,673,044	1,521,994,034
Total liabilities and net assets	\$ 1,818,168,260	1,808,261,676

Consolidated Statements of Operations

Years ended June 30, 2022 and 2021

	2022	2021
Revenues, gains and other support:		
Net patient service revenue \$	735,538,009	610,248,045
Specific purpose grants	42,134,961	34,022,809
Supplemental Medicaid reimbursement	45,106,273	43,087,063
Other	33,505,657	20,531,794
Government grants	15,521,384	38,212,294
Net assets released from restrictions and used for operations	8,060,924	6,048,978
Total revenues, gains and other support	879,867,208	752,150,983
Expenses:		
Salaries and wages	346,496,240	275,772,326
Employee benefits	64,888,077	60,251,010
Supplies and pharmaceuticals	132,578,409	106,799,380
Professional fees	105,428,876	104,003,993
Purchased services	97,060,640	74,979,224
Depreciation	49,482,423	48,688,337
Interest	6,577,147	6,680,081
Utilities	6,874,114	5,952,691
Insurance	6,302,512	3,971,534
Other	12,519,174	10,925,375
Total expenses	828,207,612	698,023,951
Income from operations	51,659,596	54,127,032
Nonoperating revenues, gains, expenses and losses:		
Contributions	9,665,084	9,847,920
Investment income	14,535,267	13,323,732
Gain on sales of investments	9,440,502	13,062,063
Other (loss)/gain on investments	(72,159,854)	50,819,906
Other gains/(losses)	462,245	(245,397)
Fundraising expenses	(7,698,883)	(6,338,486)
Net nonoperating revenues, gains, expenses and losses	(45,755,639)	80,469,738
Excess of revenues and gains over expenses and losses	5,903,957	134,596,770
Other changes in net assets without donor restrictions:		
Net unrealized (loss) on investments	(8,525,554)	(5,965,467)
Net assets released from restrictions used for purchase of property	(0,020,001)	(0,000,101)
and equipment	4,613,105	12,524,017
Grant funds used to purchase capital assets	1,130,984	2,241,509
Gift Annuity reserve	(10,805)	(22,497)
Transfer of net assets	(326,009)	(173,711)
Increase in net assets without donor restrictions \$	2,785,678	143,200,621

Consolidated Statements of Changes in Net Assets

Years ended June 30, 2022 and 2021

	Without donor restrictions	With donor restrictions	Total
Balance – June 30, 2020	\$ 1,173,443,506	194,143,857	1,367,587,363
Excess of revenues and gains over expenses and			
losses	134,596,770	_	134,596,770
Net assets released from donor restrictions and used for operations	_	(6,048,978)	(6,048,978)
Unrealized loss on investments, net	(5,965,467)	(112,703)	(6,078,170)
Contributions with donor restrictions	_	16,574,560	16,574,560
Income from investments with donor restrictions	_	1,466,060	1,466,060
Gain on sale of investments with donor restrictions	_	4,449,007	4,449,007
Other gains on investments with donor restrictions Net assets released from donor restrictions and	_	15,042,219	15,042,219
used for purchase of property and equipment	12,524,017	(12,524,017)	-
Other	-	(7,759,899)	(7,759,899)
Other than temporary impairment on investments		(50.040)	(50.040)
with donor restrictions	2 241 500	(53,910)	(53,910)
Grant funds used to purchase capital assets Annuity reserve	2,241,509 (22,497)	_	2,241,509 (22,497)
Transfer of net assets	(173,711)	173,711	(22, 431)
Change in net assets	143,200,621	11,206,050	154,406,671
Balance – June 30, 2021	1,316,644,127	205,349,907	1,521,994,034
Excess of revenues and gains over expenses and losses	5,903,957	_	5,903,957
Net assets released from donor restrictions and	0,000,001		0,000,001
used for operations	_	(8,060,924)	(8,060,924)
Unrealized (loss)/gain on investments, net	(8,525,554)	45,081	(8,480,473)
Contributions with donor restrictions	_	19,314,746	19,314,746
Income from investments with donor restrictions	-	1,331,441	1,331,441
Gain on sale of investments with donor restrictions		2,617,598	2,617,598
Other losses on investments with donor restrictions	_	(12,513,806)	(12,513,806)
Net assets released from donor restrictions and used for purchase of property and equipment	4,613,105	(4,613,105)	
Other than temporary impairment on investments	4,013,103	(4,013,103)	_
with donor restrictions	<u> </u>	(553,708)	(553,708)
Grant funds used to purchase capital assets	1,130,984		1,130,984
Annuity reserve	(10,805)	_	(10,805)
Transfer of net assets	(326,009)	326,009	
Change in net assets	2,785,678	(2,106,668)	679,010
Balance – June 30, 2022	\$ 1,319,429,805	203,243,239	1,522,673,044

Consolidated Statements of Cash Flows

Years ended June 30, 2022 and 2021

		2022	2021
Cash flows from operating activities:			
Change in net assets	\$	679,010	154,406,671
Adjustments to reconcile change in net assets to net cash provided by		,	, ,
operating activities:			
Depreciation		49,482,423	48,688,337
Net realized and unrealized losses/(gains) on investments		57,476,812	(79,912,605)
Other than temporary impairment of investments		24,170,251	2,672,809
Loss on disposition of fixed assets		101,704	753,404
Contributions for restricted endowments and capital assets		(9,372,918)	(10,426,077)
Amortization/accretion of bond premium/discount and bond issuance costs Changes in operating assets and liabilities:		(350,953)	(338,593)
Patient and other receivables		(25,349,318)	(3,356,671)
Estimated third-party payor settlements		(10,959,902)	(6,646,726)
Pledges receivable		3,026,914	6,944,471
Inventories		(1,230,641)	247,634
Other assets		(3,456,286)	(7,606,571)
Accounts payable		(2,714,702)	14,786,353
Accrued expenses, interest, grant carryover, and other liabilities Refundable advances – government grants		6,956,865 —	22,166,294 (17,031,753)
Net cash provided by operating activities	,	88,459,259	125,346,977
Cash flows from investing activities:			
Purchases of property, plant, and equipment		(24,258,584)	(31,716,199)
Purchases of investments and assets limited as to use		(214,373,480)	(329,798,183)
Proceeds from sales of investments and assets limited as to use		137,756,036	169,077,935
Net cash used in investing activities	,	(100,876,028)	(192,436,447)
Cash flows from financing activities:			
Contributions for restricted endowments and capital assets		9,372,918	10,426,077
Principal payments on long-term debt		(4,351,242)	(4,260,360)
Capital lease obligation			19,884
Payments on capital lease obligations		(26,166)	
Net cash provided by financing activities		4,995,510	6,185,601
Net decrease in cash and cash equivalents		(7,421,259)	(60,903,869)
Cash and cash equivalents:			
Beginning of year		94,149,311	155,053,180
End of year	\$	86,728,052	94,149,311
Reconciliation of cash and cash equivalents:			
Cash and cash equivalents	\$	86,554,668	93,916,413
Restricted cash for self-insurance funding		173,384	232,898
	\$	86,728,052	94,149,311
Supplemental disclosure of cash flow information	,		
Cash paid for interest	\$	6,548,123	6,632,736
Noncash operating and investing activities – purchases of property, plant, and	Ψ	0,0-10,120	5,552,750
equipment in accounts payable		3,058,978	1,028,323
Purchase of property, plant, and equipment through vendor financing and capital lease		2,363,414	
Noncash operating and investing activities – lease liability on right of use assets		2,399,668	1,814,482
. 5		, -,	, ,

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(1) Organization

Arkansas Children's, which was incorporated during December 2015, is the not-for-profit parent entity consisting of Arkansas Children's Hospital (ACH), Arkansas Children's Northwest (ACNW), Arkansas Children's Foundation (ACF), Arkansas Children's Research Institute (ACRI), Arkansas Children's Care Network (ACCN), Arkansas Children's Medical Group, PLLC (ACMG), and Sacova Insurance Company, Ltd. (SCV). ACH is a not-for-profit pediatric hospital located in Little Rock, Arkansas and serves as the only quaternary health care facility for children in the state of Arkansas. ACNW is a not-for-profit pediatric hospital located in Springdale, Arkansas which serves as the only exclusively pediatric health care facility for children in the northwest region of the state. ACF is a not-for-profit organization that exists as the fundraising branch of Arkansas Children's. ACRI operates to support, through charitable, scientific, and educational means, the mission of Arkansas Children's. ACCN is a not-for-profit pediatric statewide clinically integrated network. ACMG was formed in March 2017 to provide physician services to ACNW and ACH. SCV, formed in May 2018, is a single parent captive insurance company, domiciled in the Cayman Islands, and wholly owned by Arkansas Children's. SCV provides professional and general liability and workers' compensation insurance coverage as of July 1, 2018.

Arkansas Children's is the only healthcare system in the state solely dedicated to caring for Arkansas' children. The private, non-profit organization includes two pediatric hospitals, a pediatric research institute and USDA nutrition center, a philanthropic foundation, a nursery alliance, statewide clinics, and many education and outreach programs — all focused on fulfilling a promise to define and deliver unprecedented child health. ACH is a 336-bed, Magnet-recognized facility in Little Rock operating the state's only Level 1 pediatric trauma center, burn center, Level 4 neonatal intensive care unit, pediatric intensive care unit, pediatric surgery program with Level 1 verification from the American College of Surgeons (ACS), magnetoencephalography (MEG) system for neurosurgical planning and cutting edge research, and nationally recognized pediatric transport program. Additionally, ACH is nationally ranked by U.S. News & World Report in our pediatric subspecialties of cancer, cardiology/heart surgery, diabetes/endocrinology, nephrology, neurology/neurosurgery, pulmonology/lung surgery, and urology. ACNW, the first and only pediatric hospital in the Northwest Arkansas region, operates a 24-bed inpatient unit, a surgical unit, and outpatient clinics offering over 20 subspecialties, diagnostic services, imaging capabilities, occupational therapy services, and Northwest Arkansas' only pediatric emergency department, equipped with 30 exam rooms.

Arkansas Children's carries out its mission through its entities' core business and through community benefit work that focuses on creating "unprecedented child health" for children in Arkansas. Work to improve child health outcomes is driven by community health needs assessments (CHNA) and implementation strategies (IS) for both ACH and ACNW. CHNAs provide each hospital the opportunity to understand and prioritize community health needs through the input gathered from community members, public health experts, stakeholders, and existing data sets. CHNAs also satisfy the requirements of the Internal Revenue Service (IRS) for tri-annual needs assessments for non-profit hospitals. ACH and ACNW completed their most recent CHNA in fiscal year 2022. For each hospital, these CHNAs help inform the Implementation Strategy documents, which are the three-year plans that direct the strategic community benefit work of each hospital. ACH and ACNW each have ISs with goals and actions to address child health priorities for fiscal year 2020 through fiscal year 2022. New Implementation Plans will roll out in the fall of fiscal year 2023, and the plans will cover the timeframe of fiscal years 2023-2025.

7

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Arkansas Children's is the cornerstone organization for the Natural Wonders Partnership Council (NWPC). NWPC is a coalition of stakeholders that works in strategic partnership to define pressing child health issues in our state and organize/mobilize efforts in order to improve children's health. NWPC's collective work is focused on improving the state of child health in Arkansas.

(2) Summary of Significant Accounting Policies

(a) Principles of Consolidation

The consolidated financial statements include the accounts of Arkansas Children's, ACH, ACNW, ACF, ACRI, ACCN, ACMG, and SCV (collectively referred to as Arkansas Children's). All significant transactions among these entities have been eliminated in consolidation.

(b) Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Significant items subject to such estimates and assumptions include the determination of the useful lives of property and equipment, the allowances for implicit and explicit price concessions, reserves for professional and general liability claims, reserves for workers' compensation claims, reserves for employee healthcare claims, estimated third-party payor settlements and other contingencies. In addition, laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates related to these programs could change by a material amount in the near term.

(c) Cash, Cash Equivalents and Restricted Cash

Arkansas Children's considers all highly liquid investments, including money market mutual funds, with a maturity of less than three months when purchased to be cash equivalents.

Restricted cash includes funds restricted as to withdrawal or use. Restricted cash consists of cash held under self-insurance funding arrangements within the consolidated financial statements. Arkansas Children's applies Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-18, *Statement of Cash Flows (Topic 230) – Restricted Cash*, which requires that Arkansas Children's consolidated statement of cash flows reflect the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents.

(d) Concentration of Credit Risk

Arkansas Children's grants credit without collateral to its patients, most of whom are Arkansas residents and are insured under Medicaid or other third-party payor agreements. Arkansas Children's must comply with various reporting and operating regulations mandated by the state Medicaid program. Failure to comply with these regulations could result in Arkansas Children's losing its eligibility to receive these funds. Management is not aware of any operations or activities that would jeopardize Arkansas Children's eligibility under this program.

8

Notes to Consolidated Financial Statements June 30, 2022 and 2021

The mix of net patient receivables as of June 30, 2022 and 2021, was as follows:

	2022	2021
Medicaid and Medicare	30 %	31 %
Other third-party payors (insurance and managed care)	65	66
Patients	5	3
Total mix of net patient receivables	100 %	100 %

(e) Investments

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheet. Investment income (including interest and dividends), realized gains/losses on the sale of investments, and other gains/losses on investments are included in excess of revenues and gains over expenses and losses. Unrealized gains for internally managed available-for-sale debt securities are excluded from excess of revenues and gains over expenses and losses.

(f) Assets Limited as to Use

Assets limited as to use include assets whose use is restricted by donors, assets held by trustees under indenture agreements, assets held by Arkansas Children's wholly owned captive insurance company, and assets set aside by the Board of Directors for board-created endowments over which the Board retains control and may, at its discretion, subsequently use for other purposes.

(g) Inventories

Inventories, consisting principally of medical supplies and pharmaceuticals, are stated at the lower of cost (average cost method) or net realizable value.

(h) Costs of Borrowing

Bond discounts, premiums, and issuance costs are presented net of the associated long-term debt and amortized over the terms of the related bond issues using the effective interest method.

Arkansas Children's capitalizes interest costs on qualified construction projects as a component of the cost of related projects.

(i) Property, Plant, and Equipment

Property, plant, and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable asset, and is computed using the straight-line method based on estimated useful lives of 3 to 20 years for equipment and 10 to 40 years for buildings and land improvements.

9

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Gifts of long-lived assets used in operations, such as land, buildings, or equipment, if contributed, are reported as support without donor restrictions, and are included in excess of revenues and gains over expenses and losses, unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as support with donor restrictions. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service. Contributions restricted to the purchase of property and equipment for which restrictions are met within the same year as the contributions are received are reported as increases in net assets without donor restrictions in the accompanying consolidated financial statements.

(j) Impairment of Long-lived Assets

The carrying value of long-lived assets (including property, plant, and equipment) are evaluated for impairment whenever events or changes in circumstances indicate that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. As a result of Arkansas Children's review of long-lived assets, no impairments were recorded for the years ended June 30, 2022 and 2021.

(k) Gifts and Bequests

Arkansas Children's applies FASB ASU No. 2018-08, *Not-for-Profit Entities (Topic 958): Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made*, which requires an entity to evaluate whether transactions should be accounted for as contributions (nonreciprocal transactions) within the scope of Topic 958 or as exchange (reciprocal) transactions subject to other guidance. Additionally, an entity must determine whether a contribution is conditional and the related impact on revenue recognition.

Gifts and bequests which are not restricted by donors are classified in non-operating revenues, gains, expenses and losses. Gifts and bequests which are restricted for specific purposes by donors are recorded as additions to net assets with donor restrictions in the period the unconditional promise to give or gift is made. Expirations of donor-imposed restrictions are reported as reclassifications between net assets with donor restrictions and net assets without donor restrictions and reported in the consolidated statements of changes in net assets as net assets released from restrictions.

(I) Pledges Receivable

Promises to give, less an allowance for uncollectible amounts, are recorded as receivables in the year made at the present value of estimated future cash flows using a discount rate commensurate with the risks involved as a measure of fair value of unconditional promises to give.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(m) Net Assets

Net assets, revenue, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. The net assets of Arkansas Children's and changes therein are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Net assets with donor restrictions — Net assets subject to donor-imposed stipulations that are available for use either by the passage of time or for specific purposes; certain of these net assets are subject to donor-imposed stipulations that they be maintained permanently by Arkansas Children's. Generally, the donors of these assets permit Arkansas Children's to use all or part of the income earned on related investments for general or specific purposes.

Revenue is reported as increases in net assets without donor restrictions, unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions, unless their use is restricted by explicit donor stipulation or by law. Expirations of donor restrictions on net assets (i.e. the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as reclassifications from net assets with donor restrictions to net assets without donor restrictions. Donor-restricted contributions, whose restrictions are met in the same reporting period as the contributions are recorded, are reported as increases in net assets without donor restrictions.

(n) Endowments

Arkansas Children's endowment fund consists of individual donor restricted endowment funds and funds designated by the Board to function as endowments. As discussed in note 9(a), the net assets associated with endowment funds, including those funds designated by the Board to function as endowments, are classified and reported based on the existence or absence of donor imposed restrictions. Where the Board designates funds to function as endowments, they are classified as net assets without donor restrictions. Net assets with donor restrictions include endowments whose use by Arkansas Children's has been limited by donors to a specific time period or purpose and donor restricted endowments that have been restricted by donors, according to Arkansas Code Section 28-69-607 of the Uniform Prudent Management of Institutional Funds Act (UPMIFA), to be maintained by Arkansas Children's in perpetuity.

In accordance with FASB Accounting Standards Codification (ASC) 958, Arkansas Children's classifies as net assets with donor restrictions, (a) the original value of gifts donated to an endowment, (b) the original value of subsequent gifts to the endowment, and (c) accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the endowment fund that is not classified in the donor restricted endowment is available for appropriation for expenditure by Arkansas Children's in a manner consistent with the standard of prudence prescribed by UPMIFA.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Arkansas Children's long-term investment objective is to invest all available assets in a manner that will allow them to grow to a level that can provide a total return sufficient to meet the financial needs of Arkansas Children's and to support Arkansas Children's mission. The Arkansas Children's Investment Committee determines a spend rate percentage for each fiscal year on all donor restricted endowment funds and Board designated endowment funds without donor restriction that may be set aside for expenditure. If the market value of the donor restricted endowment fund or the Board designated endowment without donor restriction is less than the original gift amount, only the interest and dividends will be expended up to the approved spend rate; however, the Investment Committee, at its discretion, may approve to fund the remaining spend rate with earnings without donor restriction. However, if the market value is greater than the original gift amount, the Investment Committee may appropriate for expenditure the interest and dividends plus appreciation in the market value of the endowment funds over the original gift amount to fund the spend rate for that year.

To achieve its long-term rate of return objectives, Arkansas Children's relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). Arkansas Children's targets a diversified asset allocation to achieve its long-term objectives within conservative risk constraints.

(o) Income Taxes

Arkansas Children's, ACH, ACNW, ACF, ACRI, and ACMG are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and are exempt from federal income taxes on related income pursuant to Section 501(a) of the IRC. Once qualified as tax-exempt entities, Arkansas Children's, ACH, ACNW, ACF, ACRI, and ACMG are required to operate in conformity with the IRC and their tax-exempt purposes to maintain their qualification.

Arkansas Children's applies FASB ASC Topic 740 (Topic 740), *Accounting for Uncertainty in Income Taxes*. Topic 740 clarifies the accounting for uncertainty in income tax positions and provides guidance on when tax positions are recognized in an entity's financial statements and how the values of these positions are determined. Management has analyzed the tax positions taken by Arkansas Children's and has concluded that as of June 30, 2022 and 2021, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the consolidated financial statements.

ACCN is a nonstock membership organization organized in 2017 under the Arkansas Nonprofit Corporation Act of 1993. Its primary purpose is to operate a clinically integrated network. Arkansas Children's is the sole member of ACCN, and as such, ACCN is included in these consolidated financial statements. For income tax purposes, ACCN is a taxable entity.

ACCN accounts for income taxes in accordance with Topic 740, in which deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements and tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement amounts and the tax basis of assets and liabilities using currently enacted tax rates. In addition, valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Income taxes are not material to Arkansas Children's.

SCV is not subject to income or other taxes due to being domiciled in the Cayman Islands.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(p) Excess of Revenues and Gains over Expenses and Losses

The consolidated statements of operations include excess of revenues and gains over expenses and losses, which is an indicator of financial performance. Changes in net assets without donor restrictions which are excluded from excess of revenues and gains over expenses and losses, consistent with industry practice, include unrealized gains on internally managed available-for-sale debt securities, assets acquired using grants restricted for capital purposes by the granting agency, and contributions which by donor restriction are to be used for the purposes of acquiring such assets.

(q) Consolidated Statements of Operations

For purposes of presentation within the consolidated statement of operations, transactions deemed by management to be ongoing, major or central to the provision of healthcare services are reported as revenues and expenses. Peripheral or incidental transactions are reported as non-operating gains and losses.

(r) Fair Value Measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The estimated fair value amounts have been determined by Arkansas Children's using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data and develop the estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts Arkansas Children's could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

(s) Recently Issued Accounting Standards

In August 2018, the FASB issued ASU No. 2018-13, *Fair Value Measurement, Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.* This ASU intends to improve the effectiveness of disclosures in the notes to the financial statements by modifying disclosure requirements for fair value measurements. The ASU is effective for Arkansas Children's as of July 1, 2020, with early adoption permitted. The adoption of ASU No. 2018-13 did not have a material impact on the disclosures in the consolidated financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets.* This ASU changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about contributed nonfinancial assets. This ASU is effective for annual periods beginning after June 15, 2021, and interim periods with annual periods beginning after June 15, 2022, with early adoption permitted. The adoption of this standard did not have an material impact on the disclosures in the consolidated financial statements.

(t) COVID 19 Pandemic and CARES Act Funding

In December 2019, a strain of coronavirus (COVID 19) initially identified in Wuhan, China, spread around the world. The World Health Organization described the coronavirus outbreak as a "public health emergency of international concern" and on March 11, 2020 declared the outbreak of COVID 19 to be a pandemic. On March 13, 2020, President Trump declared a national public health emergency

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

with respect to the COVID 19 outbreak. In Arkansas, Governor Asa Hutchinson declared a public health emergency on March 11, 2020, in response to the first presumptive case. Orders closing schools, limiting gatherings, and closing restaurants preceded a directive from the Arkansas Department of Health effective April 3, 2020 suspending elective surgical procedures, which were subsequently reinstated, starting April 27, 2020 with certain restrictions in place. The emergency, initially declared on March 11, 2020, was renewed several times until its final expiration on May 30, 2021 at which time there were 1,938 active cases of COVID 19 in Arkansas and 194 hospitalizations in Arkansas due to COVID 19. Subsequently, the Delta Variant of COVID 19 caused infections and hospitalizations to rise at an alarming rate. On July 27, 2021, there were 15,491 active cases of COVID 19 in Arkansas and 1,025 hospitalizations. Governor Hutchison declared a public health emergency due to the catastrophic statewide impact of the Delta Variant of COVID 19 on July 29, 2021, which expired 60 days after issuance.

Initially, the COVID 19 pandemic had an adverse effect on the operations and financial position of health care provider systems, including Arkansas Children's, primarily due to reduction in overall patient volume. However, beginning in March 2021, volumes rapidly increased and have sustained through the current date resulting in the hospitals often being in critical bed status, experiencing surging emergency department volumes and incurring significant staffing challenges.

Arkansas Children's pandemic response plan has evolved as the pandemic continues to unfold. Management has taken steps to enhance operational and financial flexibility, and to react to the risks the COVID 19 pandemic presents to operations, including the following:

- Implemented certain cost reduction initiatives;
- Assessed certain planned projects and capital expenditures;
- Increased the number of telemedicine visits offered to patients; and
- Focused on retaining and supporting staff.

Management believes the extent of the COVID 19 pandemic's impact on operating results and financial condition has been and will continue to be driven by many factors, most of which are beyond Arkansas Children's control and ability to forecast. Such factors include, but are not limited to, the impact of new strains, such as the Delta and Omicron variants, on the pediatric population, the vaccination rate of Arkansas's population, and challenges of staffing sustained increased volumes. Because of these and other uncertainties, management cannot accurately estimate the length or severity of the impact of the pandemic on our business.

In the spring of 2020, many providers automatically received funds from the Provider Relief Fund (PRF), a program established by the Coronavirus Aid, Relief and Economic Security Act (CARES Act). Funds were distributed as either general distribution or targeted funds. Arkansas Children's received \$12,031,753 of general distributions in April 2020 and \$5,000,000 of safety net targeted distributions in June 2020. In July 2020, Arkansas Children's received an additional \$830,542 of general distribution funds and \$90,268 of MCD & CHIP provider targeted funds. In August 2020, Arkansas Children's received an additional \$18,647,170 of safety net targeted funds. In total, Arkansas Children's received \$36,599,733, which was recognized in fiscal year 2021, as management can attest that Arkansas Children's has incurred healthcare related expenses or lost revenues attributable to COVID 19 in

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

excess of these distributions for the reporting period January 2020 through June 2021. For the fiscal year ended June 30, 2020, based on an analysis of the initial and subsequent clarifications of the compliance and reporting requirements of the Provider Relief Fund available at that time, Arkansas Children's recorded funds received prior to June 30, 2020 of \$17,031,753 as deferred revenue on the 2020 consolidated balance sheet.

In November 2021, Arkansas Children's received \$6,897,340 of funds from the American Rescue Plan Act (ARPA) that were designated for providers who serve rural Medicaid, Children's Health Insurance Program (CHIP), and Medicare beneficiaries. In addition, Arkansas Children's received PRF Phase 4 general distribution funds of \$2,258,797 in December 2021 and \$389,247 in February 2022. In total, Arkansas Children's received \$9,545,384 from the ARPA and the PRF, which was recognized as revenue in fiscal year 2022 as management can attest that Arkansas Children's has incurred healthcare related expenses or lost revenues attributable to COVID 19 in excess of these distributions for the period of availability beginning January 2020 through June 30, 2022.

These distributions from the PRF are not subject to repayment, provided management is able to attest to and comply with the terms and conditions of the funding, including demonstrating that the distributions received have been used for healthcare related expenses or lost revenue attributable to COVID 19. Such payments are accounted for as government grants and are recognized on a systematic and rational basis as other operating revenues once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met.

The CARES Act also established the Coronavirus Relief Fund. In fiscal year 2020, Arkansas Children's recognized Coronavirus Relief Fund proceeds, distributed through the State of Arkansas, of \$2,665,721, which were available for qualifying COVID 19 related expenses through June 30, 2020. In fiscal year 2021, Arkansas Children's recognized Coronavirus Relief Fund proceeds, distributed through the State of Arkansas, of \$245,531 for qualifying COVID 19 related expenses through June 30, 2020 and \$1,367,029 for qualifying COVID 19 related expenses through December 31, 2020. In fiscal year 2022, Arkansas Children's recognized Arkansas American Rescue Plan Fund proceeds, distributed by the State of Arkansas, of \$4,476,000 qualifying COVID 19 related expenses through June 30, 2022. In addition, a total of \$1,500,000 was received in January and February of 2022 based on an agreement with the Arkansas Department of Health to provide additional hospital bed capacity for COVID patients for 20 days at \$5,000 per bed per day.

Lastly, the CARES Act provides for deferred payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020, with 50% of the deferred amount due December 31, 2021 and the remaining 50% due December 31, 2022. The Health System began deferring the employer portion of social security taxes in mid April 2020. As of June 30, 2022, \$5,483,855 of the deferred amount is included in accrued expenses. As of June 30, 2021, the Health System deferred \$10,967,709 in social security taxes, of which \$5,483,854 was included in accrued expenses and \$5,483,855 was included in other long term payables on the consolidated balance sheet. The deferred tax deposit due in December 2021 was paid during fiscal year 2022.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(3) Liquidity and Availability

Financial assets available for general expenditure within one year of June 30, 2022 and 2021 include the following:

	_	2022	2021
Cash and cash equivalents	\$	86,554,668	93,916,413
Investments		534,366,311	518,249,823
Estimated third-party payor settlements – current portion		131,439,770	138,050,512
Patient accounts receivable		106,800,778	82,554,373
Other current receivables	_	20,457,858	21,678,749
	\$_	879,619,385	854,449,870

As part of Arkansas Children's liquidity management plan, cash in excess of daily requirements for general expenditures is invested in debt and equity securities. Arkansas Children's investment portfolio contains money market funds and other liquid investments that can be drawn upon, if necessary, to meet the liquidity needs of Arkansas Children's.

(4) Other Current Receivables

The composition of other current receivables follows:

	_	2022	2021
Supplemental Medicaid receivable	\$	8,941,699	9,163,898
Pledge receivable – current portion		6,438,578	6,686,177
Grant receivables		9,886,918	7,563,114
Bequests & trusts receivable without donor restrictions		_	3,515,673
Other receivables	_	11,516,159	8,999,178
	\$_	36,783,354	35,928,040

(5) Net Patient Service Revenue and Charity Care

Patient service revenue is reported at the amount that reflects the consideration to which Arkansas Children's expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and includes variable consideration for retroactive revenue adjustments due to settlements of audits, reviews, and investigations. Generally, Arkansas Children's bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Performance obligations are determined based on the nature of the services provided by Arkansas Children's. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) receipts. Arkansas Children's believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the hospital receiving inpatient acute care services. Arkansas Children's measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and Arkansas Children's does not believe it is required to provide additional goods or services to the patient.

Because its performance obligations relate to contracts with a duration of less than one year, Arkansas Children's has elected to apply the optional exemption provided in FASB 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Arkansas Children's determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Arkansas Children's policy, and/or implicit price concessions provided to uninsured patients. Arkansas Children's determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policy, and historical experience. Arkansas Children's determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- Medicaid: Certain inpatient and outpatient services are reimbursed based on an allowable cost reimbursement methodology. Interim reimbursements for Medicaid services are generally paid at prospectively determined rates per patient day and outpatient and physician services are paid based on a fee schedule.
- **Medicare**: Certain inpatient and outpatient services are reimbursed based on an allowable cost reimbursement methodology. Interim reimbursements for inpatient services are paid based on cost-reimbursement methodologies subject to certain limits, physician services are paid based upon established fee schedules and outpatient services are paid using prospectively determined rates.
- Other: Payment agreements with certain commercial insurance carriers, health maintenance
 organizations, and preferred provider organizations provide for payment using prospectively
 determined rates per discharge, discounts from established charges, prospectively determined daily
 rates and contracted outpatient fee schedules.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge Arkansas Children's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Arkansas Children's. In addition, the contracts Arkansas Children's has with commercial payors also provide for retroactive audit and review of claims.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. Arkansas Children's also provides services to uninsured patients, and offers those uninsured patients a discount, by policy, from standard charges. Arkansas Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Adjustments arising from a change in the transaction price were not significant in 2022 or 2021.

(a) Net Patient Service Revenue

Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payors.

Patient service revenue at established rates less third-party payor contractual allowances and implicit price concessions for the years ended June 30, 2022 and 2021, consisted of the following:

		2021
Patient service revenue Less contractual allowances and implicit price concessions	\$ 1,444,230,258 (708,692,249)	1,198,657,746 (588,409,701)
Net patient service revenue	\$ 735,538,009	610,248,045

Contractual allowances represent the difference between Arkansas Children's standard charges and the amounts paid by the Medicaid and Medicare programs and other contractual payors.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Arkansas Children's net patient service revenues were derived from the following payor sources for the years ended June 30, 2022 and 2021, and are as follows:

	2022	2021
Medicaid and Medicare	59.0 %	58.5 %
Other third-party payors	40.8	41.4
Patients	0.2	0.1
	100 %	100 %

The composition of net patient service revenue based on Arkansas Children's lines of business for the years ended June 30, 2022 and 2021 is as follows:

	_	2022	2021
Inpatient	\$	429,009,423	355,884,591
Outpatient		274,955,390	226,490,321
Professional fees	_	31,573,196	27,873,133
	\$_	735,538,009	610,248,045

(b) Estimated Third-Party Payor Settlements

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreements with the payor, correspondence from the payor and Arkansas Children's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved.

Arkansas Children's provides care to patients under Medicaid, Medicare and other contractual arrangements. Certain inpatient and outpatient services rendered to Medicaid program beneficiaries are reimbursed by the State of Arkansas based on an allowable cost reimbursement methodology. Regulations require annual retroactive settlements for these costs based on cost reports filed by Arkansas Children's. These net settlements are estimated and recorded in the consolidated financial statements in the year the service is provided. The estimated net settlements at June 30, 2022, for open cost report periods from 2017 to the current year is \$197,267,805, net of a reserve of \$36,026,301 which could differ from actual settlements. Of the total net receivable of \$197,267,805 recorded as of June 30, 2022, \$65,828,035 is considered noncurrent and is therefore included in other noncurrent assets in the accompanying 2022 consolidated balance sheet. The estimated net settlements at June 30, 2021, for open cost report periods from 2015 to the current year is \$186,307,903, net of a reserve of \$34,192,015 which could differ from actual settlements. Of the total net receivable of \$186,307,903 recorded as of June 30, 2021, \$48,257,391 is considered noncurrent and is therefore included in other noncurrent assets in the accompanying 2021 consolidated balance

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

sheet. ACH's Medicaid cost reports have been audited by the Medicaid fiscal intermediary for the fiscal years ending June 30, 2015, 2016 and 2018. ACH Medicaid cost reports for fiscal years ending June 30, 2017, 2019, 2020, and 2021 are pending audit by the Medicaid fiscal intermediary. Any differences between estimated settlements and actual settlements will be recorded in the year the cost report is settled by the intermediary, typically after the fiscal intermediary's audit, or when information is available to management that a change in the estimate is warranted. During the years ended June 30, 2022 and 2021, the net patient service revenue in the accompanying consolidated statement of operations increased (decreased) by approximately \$4,200,000 and \$(5,300,000), respectively, as a result of changes to prior year estimates from final Medicaid settlements and changes in management estimates for related reserves.

(c) Supplemental Medicaid Reimbursement

State Medicaid programs incur costs for payments to health care providers that provide medical services to Medicaid recipients, and the federal government pays a portion of those costs to each state based on a formula. Under these federal rules, states are permitted to pay hospitals up to a reasonable estimate of the amount that would have been paid using Medicare payment principles. This is known as the upper payment limit (UPL). The amount of supplemental Medicaid reimbursement recorded as revenue, gains and other support for the years ended June 30, 2022 and 2021, was approximately \$45,106,000 and \$43,087,000, respectively.

(d) Charity Care

Arkansas Children's provides care to patients who meet certain criteria under its charity care policy. Arkansas Children's charity care policy provides for free or discounted care for individuals with household incomes up to 250% of poverty levels. There are financial counselors available at all registration areas of Arkansas Children's to assist in completing Medicaid, Tefra Program, Children's Medical Services, Supplemental Security Income intents and financial assistance applications. Arkansas Children's allows interest free payments to be made until the outstanding balance is paid without time constraints and also does not report to external collection agencies or take other extraordinary collection efforts. Because Arkansas Children's does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

Records are maintained to identify and monitor the level of charity care Arkansas Children's provides. These records include the amount of gross charges foregone for services under its charity care policy. Arkansas Children's estimated cost of caring for charity care patients for both the years ended June 30, 2022 and 2021, was approximately \$12,100,000. Subsequent to year end, Arkansas Children's performs a cost accounting analysis to calculate the cost of service per type of procedure. The 2022 cost will be calculated based on the audited financial statement data; therefore, it was not available at the time of the issuance of the consolidated financial statements in order to disclose the 2022 amount. Therefore, Arkansas Children's calculated the 2022 charity cost by using the 2021 actual allocated cost to charge ratio for charity care adjusted for overall changes in the current year cost profile and applying it to current year charity care charges.

Arkansas Children's applies the provisions of FASB ASU 2010-23, *Health Care Entities (Topic 954): Measuring Charity Care for Disclosure*, whereby cost is used as the measurement basis for charity care disclosure purposes.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(6) Investments and Assets Limited as to Use

At June 30, 2022 and 2021, investments and assets limited as to use consisted of the following:

	_	2022	2021
Investments	\$	534,366,311	518,249,823
Assets limited as to use:			
Board designated investments	\$	269,126,693	285,940,026
Restricted cash for self-insurance funding arrangements		173,384	232,898
Restricted investments:			
Endowments with donor restrictions		121,603,173	126,471,525
Other investments with donor restrictions		909,783	955,538
Other investments for self-insurance funding			
arrangements		3,119,463	2,636,651
Investments held by trustee under bond agreements	_	3,106,904	3,008,383
Total assets limited as to use		398,039,400	419,245,021
Less amounts classified as current	_	(5,029,175)	(4,652,525)
Assets limited as to use – noncurrent	\$_	393,010,225	414,592,496

Included with the investments and assets limited as to use balances disclosed above are U.S. government obligations of approximately \$579,877,000 and \$548,053,000 which are considered available for sale as of June 30, 2022 and 2021, respectively. These investments are managed internally and are not actively traded. The remaining amounts within the investments and assets limited as to use above are externally managed and are actively traded.

The trust indentures related to the outstanding bonds (see note 8) require the establishment of certain funds to be held and controlled by an independent trustee as long as the bonds remain outstanding. Such funds are to be used to pay principal and interest on the debt and to finance construction.

Funds held by trustee under bond indenture agreements as of June 30, 2022 and 2021, were invested in federal government obligations, which are mutual funds backed by U.S. Treasury securities, State and Local Government Series (SLGS) and U.S. Treasury securities and consisted of the following:

	_	2022	2021
Series 2016 Refunding Bond Fund (ACH) Series 2016 Bond Fund (ACNW)	\$	1,375,642 1,731,262	1,278,247 1,730,136
Total	\$	3,106,904	3,008,383

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(7) Property, Plant, and Equipment, net

A summary of property and equipment, net, is as follows:

	_	2022	2021
Land and improvements	\$	45,180,747	45,180,747
Buildings		537,090,833	528,270,618
Equipment		274,542,275	263,363,187
Construction in progress	_	7,621,894	6,847,871
Total property, plant and equipment		864,435,749	843,662,423
Less accumulated depreciation	_	(475,953,435)	(432,534,547)
Property, plant, and equipment, net	\$	388,482,314	411,127,876

Construction in progress as of June 30, 2022 primarily consists of routine replacement and expansion projects at various Arkansas Children's facilities. The estimated total remaining cost to complete these projects as of June 30, 2022 is approximately \$4,442,728. Depreciation expense was \$49,482,423 and \$48,688,337 in 2022 and 2021, respectively.

(8) Long-term Debt

A summary of long-term debt as of June 30, 2022 and 2021, is as follows:

	_	2022	2021
Arkansas Development Finance Authority Revenue Bonds Series 2013, due in amounts of \$45,947 on October 1 and November 1, 2013 and \$184,074 on the first day of each successive month thereafter through September 2023, bearing interest at a fixed rate of 1.95%, collateralized by			
certain equipment	\$	2,384,761	4,251,003
Pulaski County, Arkansas Hospital Revenue Refunding			
Bonds, Series 2016, due in variable amounts through			
March 1, 2039, bearing interest at fixed rates ranging		05 000 000	05 400 000
from 2% to 5%, collateralized by ACH revenues		85,080,000	85,190,000
City of Springdale Public Facilities Board Hospital Revenue Bonds, Series 2016 (Arkansas Children's Northwest			
Project), due in variable amounts through March 1, 2036,			
bearing interest at fixed rates ranging from 2% to 5%,			
collateralized by Arkansas Children's revenue		64.265.000	66,640,000
conditionalized by American Chinaron Choraca	_	01,200,000	
		151,729,761	156,081,003

22 (Continued)

0000

0004

Notes to Consolidated Financial Statements June 30, 2022 and 2021

	_	2022	2021
Plus unamortized premium on the 2016 revenue and 2016 revenue refunding bonds Less unamortized bond issuance costs on the 2016	\$	7,934,056	8,346,151
revenue refunding, and 2013 and 2016 revenue bonds	_	(1,129,983)	(1,191,125)
Total		158,533,834	163,236,029
Less amounts due within one year	_	(4,807,611)	(4,351,338)
Long-term debt less current maturities	\$_	153,726,223	158,884,691

Scheduled maturities of long-term debt for the years ending June 30 are as follows:

2023	\$ 4,807,611
2024	6,712,150
2025	6,540,000
2026	6,865,000
2027	7,070,000
Thereafter	119,735,000
Total	\$ 151,729,761

Arkansas Children's long-term debt agreements include certain restrictive covenants with which ACH and ACNW must comply, including the debt service coverage ratio and total debt to capitalization.

(9) Net Assets with Donor Restrictions

Net assets with donor restrictions at June 30, 2022 and 2021, are available for the following:

	_	2022	2021
Health care services:			
Capital expenditures	\$	1,084,683	1,019,703
Arkansas Children's Northwest		12,554,953	13,828,444
Research funding		10,250,250	10,558,794
Land receivable		6,590,000	6,590,000
Pine Bluff Clinic		1,940,510	1,673,618
Other spendable gifts, trusts and pledges		49,219,670	45,207,823
Endowments with donor restrictions	_	121,603,173	126,471,525
Total	\$_	203,243,239	205,349,907

Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Net assets with donor restrictions are classified on the accompanying consolidated balance sheet in cash and cash equivalents, other current receivables, pledges receivable – noncurrent, and assets limited as to use – noncurrent.

Net assets restricted for Arkansas Children's Northwest include pledges and cash gifts designated for ACNW, which includes capital and noncapital components.

During 2022 and 2021, net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes in the amount of \$8,060,924 and \$6,048,978, respectively. In addition, net assets were released from donor restrictions and used for the purchase of property and equipment in the amount of \$4,613,105 and \$12,524,017 for June 30, 2022 and 2021, respectively.

(a) Endowment Net Assets

The following table summarizes the changes in endowment net assets for the fiscal years ended June 30, 2022 and 2021:

	_	Board designated	With donor restrictions	Total
Endowment net assets, June 30, 2020	\$	230,805,441	103,843,843	334,649,284
Investment return: Investment income Net gains (realized and unrealized)	_	3,864,042 47,356,072	1,466,060 19,323,290	5,330,102 66,679,362
Total investment return		51,220,114	20,789,350	72,009,464
Contributions Transfers Appropriation of endowment asset for		7,615,936	4,827,952 1,061,833	4,827,952 8,677,769
expenditures	_	(3,701,465)	(4,051,453)	(7,752,918)
Endowment net assets, June 30, 2021	_	285,940,026	126,471,525	412,411,551
Investment return: Investment income Net losses (realized and unrealized)	_	4,098,036 (33,496,506)	1,331,441 (10,401,884)	5,429,477 (43,898,390)
Total investment return		(29,398,470)	(9,070,443)	(38,468,913)
Contributions Transfers Appropriation of endowment asset for		 19,850,000	7,618,908 307,876	7,618,908 20,157,876
expenditures	_	(7,264,863)	(3,724,693)	(10,989,556)
Endowment net assets, June 30, 2022	\$_	269,126,693	121,603,173	390,729,866

Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(10) Insurance and Legal

Arkansas Children's is self-insured with respect to claims paid for employee health care. Estimates of health claims incurred but unpaid as of June 30, 2022 and 2021, are accrued based on Arkansas Children's past experience, as well as other considerations including the nature of claims and relevant trends. As of June 30, 2022, and 2021, Arkansas Children's has accrued a liability in the accrued expenses and other liabilities caption within the accompanying consolidated balance sheets for estimated incurred but unpaid claims of approximately \$1,857,000 and \$1,853,000, respectively. The expenses related to claims paid during the years ended June 30, 2022 and 2021, were approximately \$21,409,000 and \$20,256,000, respectively, and are included in employee benefits expense. Arkansas Children's maintains stop-loss insurance coverage with respect to the employer share of medical insurance claim costs. Under the terms of the stop-loss insurance plan, the stop-loss insurance carrier is to reimburse 100% of the cost of each covered person's paid claims in excess of \$750,000 for both plan years ended June 30, 2022 and 2021, with no maximum annual benefit per person; however, a plan level deductible called an "aggregating specific deductible" must be satisfied by the whole group medical insurance plan before any reimbursements are paid to Arkansas Children's by the stop-loss carrier for an individual stop-loss claim. The plan level aggregating specific deductible amount was \$70,000 for the fiscal years ended June 30. 2022 and 2021. The purpose of the aggregating specific deductible is to reduce annual fixed stop-loss premium costs during the plan year where the group medical insurance plan experiences low volume or no high dollar medical claims.

SCV, a captive insurance company, was formed to provide professional and general liability and workers' compensation insurance coverage to Arkansas Children's effective July 1, 2018. All claims incurred from July 1, 2018 forward are covered under the captive, and the tail liability for professional and general liability claims not reported prior to July 1, 2018 remains \$190,000. Under the terms of the captive, coverage for professional and general liability is \$1,000,000 indemnity and expense limit on a mature claims made basis. Workers' compensation coverage is limited to \$500,000 per claim. An estimated liability of \$2,145,000 and \$295,000 was accrued in the accrued expenses and other liabilities caption within the consolidated balance sheets as of June 30, 2022 for professional and general liability and workers' compensation insurance coverage, respectively. Arkansas Children's carries an umbrella liability policy in the amount of \$20,000,000 to cover professional and general liability claims in excess of \$1,000,000. Arkansas Children's also maintains excess worker's compensation coverage which will reimburse 100% of the cost of each employee's claim in excess of \$500,000.

Arkansas Children's maintains Directors & Officers liability insurance with estimated liabilities of approximately \$46,000 and \$79,000 accrued at June 30, 2022 and June 30, 2021, respectively, for deductibles.

Under Arkansas law, Arkansas Children's has been recognized as a charitable institution that is immune from tort liability or execution in the enforcement of a judgment in a tort action. There is no assurance that this doctrine of charitable immunity will be held to apply to Arkansas Children's in future litigation, but previously decided case law would support such a holding.

There are no proceedings pending against Arkansas Children's, or to its knowledge, threatened against it, which may not be adequately covered by Arkansas Children's reserves and insurance policies or which, in the opinion of management, could have a materially adverse effect on Arkansas Children's consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(11) Employee Benefit Plans

Arkansas Children's has a 403(b) plan for the benefit of substantially all of its employees. Employer contributions are made based on the employee's respective contributions, and are vested based on the years of service of the individual employees. Plan expense recorded in employee benefits expense in the accompanying consolidated statements of operations was approximately \$7,594,000 and \$6,555,000 for the years ended June 30, 2022 and 2021, respectively.

Arkansas Children's has a defined contribution retirement plan covering substantially all employees meeting certain eligibility requirements. Employer contributions to the plan are made at the discretion of the Arkansas Children's Board of Directors. Arkansas Children's made contributions of 2% of eligible employees' compensation for fiscal years 2022 and 2021. Contributions accrued for the plan for the years ended June 30, 2022 and 2021, were approximately \$4,730,000 and \$6,553,000, respectively, with the related liability included in accrued expenses and other liabilities in the accompanying consolidated balance sheets.

Arkansas Children's has a nonqualified deferred compensation plan under IRC Section 457(b). Arkansas Children's reports a liability in accrued expenses and other liabilities in the accompanying consolidated balance sheets with a corresponding investment asset of approximately \$3,842,000 and \$3,952,000 as of June 30, 2022 and 2021, respectively. The assets in the plan remain the property of the employer until paid or made available to participants, subject only to the claims of Arkansas Children's general creditors.

Arkansas Children's established a nonqualified deferred compensation plan under IRC Section 457(f) effective June 30, 2014. The plan is a defined contribution plan which covers certain executive employees. The net expense charged to earnings for fiscal years 2022 and 2021 was approximately \$679,000 and \$484,000, respectively, with the related liability included in accrued expenses and other liabilities in the accompanying consolidated balance sheets. The expense is generally calculated based on a percentage of the annual base pay of the covered executive employees plus an amount for interest as determined in the plan.

(12) Related-Party Transactions

Several Arkansas Children's board members are employed by the University of Arkansas for Medical Sciences (UAMS). During the years ended June 30, 2022 and 2021, contracts for professional services between Arkansas Children's and UAMS resulted in Arkansas Children's incurring expenses of approximately \$101,445,000 and \$86,025,000, respectively, to UAMS. During the years ended June 30, 2022 and 2021, Arkansas Children's also recorded revenue of approximately \$5,300,000 and \$5,000,000, respectively, from UAMS. In addition, ACH bills and collects physician outpatient professional fees for patient care performed at ACH and ACNW, which resulted in ACH and ACNW recording approximately \$25,740,000 of net revenue for the fees billed with approximately \$24,402,000 of collected fees, net of expenses, being remitted to UAMS for the year ended June 30, 2022, and approximately \$23,719,000 of net revenue for the fees billed with approximately \$22,415,000 of collected fees, net of expenses, being remitted to UAMS for the year ended June 30, 2022, and 2021, the Arkansas Children's payable due to UAMS was approximately \$7,700,000 and \$6,740,000, respectively. As of June 30, 2022, and 2021, the Arkansas Children's receivable due from UAMS was approximately \$277,000 and \$45,000, respectively.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

During the years ended June 30, 2022 and 2021, Arkansas Children's also paid approximately \$7,547,000 and \$8,370,000, respectively, to a company affiliated with a member of the ACF Board of Directors for construction projects. During the years ended June 30, 2022 and 2021, Arkansas Children's paid approximately \$1,426,000 and \$1,197,000, respectively, for goods and services from various other related parties.

A physician hospital organization (PHO), established in 1994, is 50% owned by ACH and participating physicians, respectively. The PHO identifies contract opportunities for its members. Also, the Arkansas Children's Hospital Auxiliary raises funds for and renders services to ACH and its patients. The activities of these entities are not considered material in relation to the consolidated financial statements of Arkansas Children's.

(13) Fair Value Hierarchy of Financial Instruments

In accordance with FASB ASC Topic 820 (Topic 820), *Fair Value Measurement*, Arkansas Children's has categorized its financial instruments, based on priority of inputs used in valuation techniques, into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within multiple levels of hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that Arkansas Children's has the ability to access. Valuation adjustments are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

Level 2 – Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Arkansas Children's applies ASU 2015-07, Fair Value Measurement (Topic 820) — Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share. Topic 820 permits an entity, as a practical expedient, to measure the fair value of certain investments using the net asset value per share of the investment.

Fair value of a financial instrument is generally defined as the amount at which the instrument could be exchanged in a current transaction between willing parties, as expanded by the previously described Topic 820. For cash and cash equivalents, accounts receivable, accrued interest, estimated third-party payor settlements, accounts payable, and accrued interest payable, the carrying amount is a reasonable estimate of fair value due to the short-term nature of these assets and liabilities, as such these amount are considered to be level 1 financial instruments.

Investments and assets limited as to use are carried on the consolidated balance sheets at estimated fair value. Estimated fair values of investments and assets limited as to use are based on quotes from published market sources. Other assets-mineral interests are reported at fair value as determined by an independent appraiser using the income approach method.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Pledge receivables are reported at the net present value of expected future cash flows. Pledge receivables were \$24,769,025 and \$27,795,938 as of June 30, 2022 and 2021, respectively, and have not been included in the fair value tables that follow as these assets are carried at the net present value of expected future cash flows.

The following tables set forth, by level within the fair value hierarchy, a summary of Arkansas Children's assets measured at fair value on a recurring basis at June 30, 2022 and 2021.

	_	Fai	r value measuren	nents at June 30, 20	22
	_	Quoted prices in active			
		markets for identical assets (Level 1)	Other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	_	<u> </u>			
Investments and assets limited					
as to use: Cash restricted for self-insurance	\$	173,384			173,384
U.S. government obligations	Ψ	173,304	 595,926,488	_	595,926,488
Corporate stocks:		_	393,920,400	<u>—</u>	393,920,400
Consumer staples		17,254,312			17,254,312
•		15,448,037	_	_	
Consumer discretionary			_	_	15,448,037
Energy		17,142,735	_	_	17,142,735
Financials		30,828,329	_	_	30,828,329
Health care		35,898,992	_	_	35,898,992
I ndustria I s		21,143,767	_	_	21,143,767
Information technology		52,118,376	_	_	52,118,376
Materials		22,864,742	_	_	22,864,742
Telecommunication			_	_	
services		19,137,734	_	_	19,137,734
Utilities		4,620,148	_	_	4,620,148
Real estate		2,947,160	_	_	2,947,160
Other		188,341	_	_	188,341
Mutual funds:					
Equities		40,352,146	_	_	40,352,146

Notes to Consolidated Financial Statements June 30, 2022 and 2021

		Fai	r value measurem	nents at June 30, 202	22
		Quoted prices in active markets for identical assets (Level 1)	Other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Corporate debt:					
Banks	\$	_	9,851,027	_	9,851,027
Consumer goods		_	12,855,782	_	12,855,782
Energy power		_	3,691,128	_	3,691,128
Energy company		_	1,967,485	_	1,967,485
Industrials		_	1,353,967	_	1,353,967
Other financials		_	2,195,740	_	2,195,740
Technology		_	9,187,696	_	9,187,696
Telephone		_	3,860,797	_	3,860,797
Transportation		_	653,021	_	653,021
Health care		_	323,245	_	323,245
Other		_	1,524,804	_	1,524,804
Agencies		_	5,589,031	_	5,589,031
Certificates of deposit		_	200,393	-	200,393
Mutual funds		3,106,904		<u> </u>	3,106,904
Total investments and assets limited as to use	\$	283,225,107	649,180,604	<u>_</u>	932,405,711
	Ψ.		310,100,001		232,100,711
Other noncurrent assets:					
Mineral interests	\$	_	588,000	_	588,000

Notes to Consolidated Financial Statements June 30, 2022 and 2021

	_	Fai	r value measuren	nents at June 30, 20	21
	-	Quoted prices in active markets for identical	Other observable	Significant unobservable	
	_	assets (Level 1)	inputs (Level 2)	inputs (Level 3)	Total
Investments and assets limited	· <u>-</u>	_			
as to use:					
Cash restricted for self-insurance	\$	232,898	_	_	232,898
U.S. government obligations	·	_	561,563,196	_	561,563,196
Corporate stocks:			, ,		, ,
Consumer staples		17,493,920	<u> </u>	<u> </u>	17,493,920
Consumer discretionary		19,607,136	_	_	19,607,136
Energy		11,852,481	_	_	11,852,481
Financials		35,426,875	_	_	35,426,875
Health care		35,479,969	_	_	35,479,969
Industrials		24,350,763	_	_	24,350,763
Information technology		60,448,097	_	_	60,448,097
Materials		22,990,096	_	_	22,990,096
Telecommunication services		22,628,552	_	_	22,628,552
Utilities		4,504,195	_	_	4,504,195
Real estate		385,652	_	_	385,652
Other		2,750,672	_	_	2,750,672
Mutual funds:					
Equities		52,922,493	_	_	52,922,493
Corporate debt:					
Banks		_	13,337,398	_	13,337,398
Consumer goods		_	5,893,852	_	5,893,852
Energy power		_	6,834,641	-	6,834,641
Energy company		_	3,606,120	_	3,606,120
Industrials		_	2,704,771	-	2,704,771
Other financials		_	1,615,075	_	1,615,075
Technology		_	2,835,201	_	2,835,201
Telephone		_	9,394,520	_	9,394,520
Transportation		_	4,642,883	_	4,642,883
Health care		_	728,923		728,923
Other		_	3,353,045	_	3,353,045

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

	_	Fai	r value measuren	nents at June 30, 20	21
		Quoted prices in active markets for identical assets (Level 1)	Other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Agencies	\$	_	6,702,644	_	6,702,644
Certificates of deposit		_	200,393	_	200,393
Mutual funds		3,008,383			3,008,383
Total investments and assets limited as to		0.44.000.400	200 440 000		
use	\$.	314,082,182	623,412,662		937,494,844
Other noncurrent assets: Mineral interests	\$	_	296,058	<u> </u>	296,058

Notes to Consolidated Financial Statements June 30, 2022 and 2021

(14) Functional Expense

Total operating expenses, including nonoperating fundraising expenses, classified by their natural classification on the consolidated statements of operations are presented in their functional classifications as follows for the years ended June 30:

				2022	27			
	T	Program activities	S		S	Supporting activities	se	
	=		- -		Non-			
	services	Research	l otal program	deneral and administrative	services	Fundraising	l otal supporting	Total
Salaries and w ages	\$ 309,252,467	19,771,797	329,024,264	16,944,681	24,533	4,325,417	21,294,631	350,318,895
Employee benefits Supplies and	57,011,153	4,237,132	61,248,285	3,524,911	5,152	869,185	4,399,248	65,647,533
pharmaceuticals	129,539,982	2,789,431	132,329,413	239,258	2,275	362,456	603,989	132,933,402
Professional fees	105,419,301	6,824	105,426,125	2,313		438	2,751	105,428,876
Purchased services	83,766,863	9,264,971	93,031,834	3,679,342	117,625	2,225,324	6,022,291	99,054,125
Depreciation	45,621,693	2,983,805	48,605,498	825,088	I	139,851	964,939	49,570,437
Interest	6,499,970	54,007	6,553,977	17,241	I	141,184	158,425	6,712,402
Utilities	5,827,735	799,890	6,627,625	187,822	I	58,691	246,513	6,874,138
Insurance	1,528,787	ĺ	1,528,787	3,141,381	1,632,345	l	4,773,726	6,302,513
Other	10,526,574	776,621	11,303,195	1,177,571	21,385	562,023	1,760,979	13,064,174
Total	\$ 754,994,525	40,684,478	795,679,003	29,739,608	1,803,315	8,684,569	40,227,492	835,906,495

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

		1		2021				
		Program activities	S		nS Sn	Supporting activities	es	
					Non-			
	Healthcare	gi.	Total	General and	Healthcare		Total	
	services	Research	program	administrative	services	Fundraising	supporting	Total
Salaries and w ages	₩	2 17,408,157	259,100,169	16,300,749		3,901,190	20,201,939	279,302,108
Employee benefits	51,231,852	3,658,147	54,889,999	5,276,940	1	754,154	6,031,094	60,921,093
Supplies and								
pharmaceuticals	103,710,938	3 60,530	103,771,468	205,062	2,100	237,582	444,744	104,216,212
Professional fees	104,858,507	7 1,823,305	106,681,812	115,148	ĺ	320	115,468	106,797,280
Purchased services	67,249,779	3,874,887	71,124,666	3,537,719	107,925	1,397,493	5,043,137	76,167,803
Depreciation	44,444,432		47,483,032	1,139,751	ĺ	153,906	1,293,657	48,776,689
Interest	6,595,476	5 53,961	6,649,437	24,463	ĺ	114,210	138,673	6,788,110
Utilities	5,004,703	7	5,704,991	199,681	ĺ	62,342	262,023	5,967,014
Insurance	489,286		489,286	2,573,220	909,028	I	3,482,248	3,971,534
Other	9,202,510	530,574	9,733,084	1,138,844	32,536	550,130	1,721,510	11,454,594
Total	\$ 634,479,495	31,148,449	665,627,944	30,511,577	1,051,589	7,171,327	38,734,493	704,362,437

equivalent employees of the related program activities, supporting activities and fundraising. Fundraising expenses functional classification in the tables above differs from its natural classification on the statement of operations by \$985,686 and \$832,841 as of June 30, 2022 and 2021, expenses require allocation on a reasonable basis that is consistently applied. The allocations are primarily based on total revenues and full-time The consolidated financial statements report certain categories of expenses that are attributable to more than one function. Therefore, these respectively due to the aforementioned allocations.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(15) Commitments and Contingencies

(a) Federal Awards

ACRI receives federal awards to support its research efforts. These grants are subject to financial and compliance audits by the granting agencies. The amount of expenditures, if any, which may be disallowed by the granting agency cannot be determined at this time; however, management expects such amounts, if any, to be immaterial.

(b) Leases

In February 2016, the FASB issued ASU 2016-02, *Leases* (Topic 842), which introduces a right of use model which requires lessees to recognize all leases, other than short term leases with a maximum possible term of one year or less, on their balance sheet. Also, the amortization of these leases will be dependent on the portion of the underlying asset being utilized during the lease term. In July 2018, the FASB issued 2018-11, *Leases Targeted Improvements*, which provides entities with an additional (and optional) transition method to adopt the new leases standard and a practical expedient for non lease components. In May 2020, the FASB issued ASU 2020-05, *Revenue from Contracts with Customers* (Topic 606) *and Leases* (Topic 842), which changed the effective date for the lease standard for certain companies. Arkansas Children's adopted ASU 2016-02, ASU 2018-11, and ASU 2020-05 effective July 1, 2020 using a modified retrospective approach. The primary effect of adopting the new standard is a \$5,101,562 increase in right of use assets and lease obligations for current operating leases as of July 1, 2020 which includes the fiscal 2021 recognized lease liability of \$1,814,482.

Arkansas Children's has entered into non-cancelable operating leases for equipment and facilities. Arkansas Children's has determined whether each arrangement is a lease at the inception of the contract. Leases with an initial term of twelve months or less are not recorded on the accompanying consolidated balance sheets.

Arkansas Children's has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, Arkansas Children's elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use (ROU) assets represent Arkansas Children's right to use an underlying asset during the lease term and lease liabilities represent Arkansas Children's obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. Arkansas Children's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of Arkansas Children's leases do not provide an implicit rate, Arkansas Children's uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Arkansas Children's considers recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating it incremental borrowing rates. Fixed lease expense is recognized on a straight-line basis over the lease term, while variable payments are recognized in the period incurred.

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

Operating lease expense for the years ended June 30, 2022 and 2021 was approximately \$3,805,000 and \$2,694,000, respectively. The undiscounted future lease payments under non-cancelable operating leases and reconciliation to the corresponding liability included in the accompanying 2022 consolidated balance sheet follow:

Years ending	June 30:		
2023		\$	2,301,773
2024			1,503,247
2025			1,157,663
2026			1,011,235
2027			735,682
Thereafter		_	5,482,117
	Total lease payments		12,191,717
Less Interest		_	1,870,846
	Present value of lease		
	liabilities	\$_	10,320,871

At June 30, 2022, the weighted-average remaining lease term is 9.92 years and the weighted average discount rate is 3.24%.

(16) Donor-restricted Gifts and Pledges Receivable

Amounts of net pledges receivable (at net present value discounted at a rate of 3.25% for the years ended June 30, 2022 and 2021, respectively) as of June 30, 2022 and 2021 are as follows:

	2022 Net pledges receivable with donor restrictions	
Due in less than one year Due in one to five years Due in more than five years	\$ 6,438,578 5,678,725 1,688,931	6,686,177 6,902,434 2,249,537
Total	\$ 13,806,234	15,838,148

Land receivable, valued at \$6,590,000 included in pledges receivable as of June 30, 2022 and 2021, is not shown above as the various properties are held in trust for an expected period of between 10 to 25 years.

35 (Continued)

Notes to Consolidated Financial Statements
June 30, 2022 and 2021

Maturities of trusts receivable are not shown above as the maturities of these receivables are dependent upon the life expectancies of the related income beneficiaries. Pledges receivable include donor-restricted trust receivables (at net present value), which totaled approximately \$4,373,000 and \$5,368,000 at June 30, 2022 and 2021, respectively.

The allowance for uncollectible pledges receivable totaled approximately \$609,000 and \$737,000 as of June 30, 2022 and 2021, respectively. The discount relating to pledges receivable totaled approximately \$667,000 and \$1,063,000 as of June 30, 2022 and 2021, respectively.

(17) Subsequent Events

Arkansas Children's has evaluated subsequent events through October 27, 2022, the date on which the consolidated financial statements were issued, and determined that there are no subsequent events identified that would warrant any adjustments, or disclosure in, the consolidated financial statements.



Single Audit Reports June 30, 2022

Table of Contents

	Page
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	1
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance, Schedule of Expenditures of State of Arkansas Financial Assistance and Schedule of Units of Service	3
Schedule of Expenditures of Federal Awards	6
Schedule of Expenditures of State of Arkansas Financial Assistance	9
Notes to Schedules of Expenditures of Federal Awards and Expenditures of State of Arkansas Financial Assistance	10
Schedule of Units of Service	11
Schedule of Findings and Questioned Costs	12



KPMG LLP Triad Centre III Suite 450 6070 Poplar Avenue Memphis, TN 38119-3901

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

The Board of Directors Arkansas Children's Little Rock, Arkansas:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Arkansas Children's, which comprise Arkansas Children's consolidated balance sheet as of June 30, 2022, and the related consolidated statements of operations, changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 27, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Arkansas Children's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Arkansas Children's internal control. Accordingly, we do not express an opinion on the effectiveness of Arkansas Children's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of Arkansas Children's consolidated financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Arkansas Children's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Arkansas Children's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Arkansas Children's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Memphis, Tennessee October 27, 2022



KPMG LLP Triad Centre III Suite 450 6070 Poplar Avenue Memphis, TN 38119-3901

Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance, Schedule of Expenditures of State of Arkansas Financial Assistance and Schedule of Units of Service

The Board of Directors Arkansas Children's Little Rock, Arkansas:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Arkansas Children's compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of Arkansas Children's major federal programs for the year ended June 30, 2022. Arkansas Children's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, Arkansas Children's complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Arkansas Children's and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Arkansas Children's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Arkansas Children's federal programs.



Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Arkansas Children's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Arkansas Children's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and
 perform audit procedures responsive to those risks. Such procedures include examining, on a test basis,
 evidence regarding Arkansas Children's compliance with the compliance requirements referred to above
 and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Arkansas Children's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of Arkansas Children's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.



Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance, Schedule of Expenditures of State of Arkansas Financial Assistance and Schedule of Units of Service

We have audited the consolidated financial statements of Arkansas Children's as of and for the year ended June 30, 2022, and have issued our report thereon dated October 27, 2022, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. In addition, the accompanying schedule of expenditures of State of Arkansas financial assistance is presented for the purposes of additional analysis as required by the State of Arkansas and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedules of expenditures of federal awards and expenditures of State of Arkansas financial assistance are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of units of service is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information has not been subjected to the auditing procedures applied in the audit of the consolidated financial statements, and accordingly, we do not express an opinion or provide any assurance on it.

KPMG LLP

Memphis, Tennessee March 15, 2023

Schedule of Expenditures of Federal Awards

Year ended June 30, 2022

Lung Diseases Research 93.838 University of Pennsylvania 583403 41,011 Lung Diseases Research 93.838 Divke University A033918 8,922 Lung Diseases Research 93.838 University of Michigan 00015491 947 Lung Diseases Research 93.838 Regents of the UCSF 12795sc 60,944	Federal grantor/pass-through grantor/program or cluster title	Assistance Listing Number (ALN)	Pass-through entity	Pass-through entity identifying number	Expenditures recognized	Amounts passed through to subrecipients
Application Research Research Research (1907) 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1907 1	Research and Development Cluster:					
Page	Agricultural Research Basic and Applied Research	10.001 10.001				283,664
The LLD Experiment of Agricultural Vision Received for Agricultura	Total for Program				9,695,334	283,664
The LLD Experiment of Agricultural Vision Received for Agricultura	Agricultural and Food Research Initiative	10.310			88.218	_
1.5. Columbia University of Maria University Columbia University Wat 1099 16 - 1020 2.88						283,664
1.5. Quantimative in terms arounce 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5. 1.5	U.S. Department of Defense:	12.420	Columbia University	W81XWH-19-1-0266		
Food and Clay Administration 1.0 100	U.S. Department of Health and Human Services: Centers for Disease Control and Prevention:	02.072	LIAMO	N/A		
Post of Cong Administration Research 2.000 June Negation Liverarity NA 2.000 June Negation Liverary Na 2.000 June Negation Liverarity Na 2.000 June Negation Liverary Na 2.000 June Negation	·	93.073	UAWS	N/A	62,730	_
Maneral and Claff Health Frequence (Febrush Clambrace) (Febrush	Food and Drug Administration Research	93.103	Johns Hopkins University	N/A	2,598	-
Procession of Florage Procession Program	Maternal and Child Health Federal Consolidated Programs	93.110	University of Texas Health Science Center of Houston	0012728G	7,648	-
Total for Program Autora Canton of Sub-Programs Total for Program Total for Program Autora Canton of Sub-Programs Total for Program Total for Program Autora Canton of Sub-Programs Total for Program Total for Program Autora Canton of Sub-Programs Total for Program Total for Progra		93 113			23 477	_
Reseach and Training in Complementary and Holigation Health 1921 1972 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1973 1						
Research and Training'in Conferendrating' and Intigrative Health 92.713 Most State 92.714 1.380 2.411 1.380 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.281 1.	Total for Program				101,902	
National Center on Steep Disorders Research Programs						
Accide Research Programs 93.277 Rode Isual Health Gormona Center-New Orleans 19.2.1-504 20.2.1-324 4.6.888 22.5.571 Total for Program 93.279 Rode Isual Heaptal Heaptal 93.279 Rode Isual Heaptal Heaptal 93.279 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,372-0.1 92.5.579 1971,37	Total for Program				62,411	
Acotol Research Programs Toal for Program Ding Abuse and Addiction Research Programs Ding Abuse and Addiction Research Programs Ding Abuse and Addiction Research Programs Toal for Program Toal for Program Tam-Nille Research Support National Center for Advancing Translational Sciences 33.301 UAMS S2986 205.567 Naring Research Naring Naring Research Naring Research Naring Research Naring Naring Research Naring Research Naring Naring Research Naring Research Naring Naring Research Naring Naring Research Naring Naring Naring Naring Naring Naring Naring N	National Center on Sleep Disorders Research	93.233	Johns Hopkins University	2003727945 / 20038727945	36,431	_
Display Disp			LSU Health Sciences Center-New Orleans Rhode Island Hospital			
Display Disp	Total for Program				68,258	_
Trans-Hilf Research Support	Drug Abuse and Addiction Research Programs Drug Abuse and Addiction Research Programs				153,664	
Trans-litt Research Support 93.310	Total for Program				666.069	
National Center for Advancing Translational Sciences 93.360 UAMS 52966 205.567 Nursing Research 93.361 Washington University WU-19-154 / WU-20-194 62.968 Cancer Treatment Research 93.365 Children's Repolated of Philadelphia 950080200-01C 21.000 Cancer Treatment Research 93.365 Children's Repolated of Philadelphia 950080200-01C 21.000 Cancer Treatment Research 93.365 Children's Repolated of Philadelphia 950080200-01C 21.000 Cancer Treatment Research 93.365 Children's Repolated of Philadelphia 950080200-01C 21.000 Cancer Treatment Research 93.365 Children's Repolated of Philadelphia 950080200-01C 21.000 Cancer Treatment Research 93.365 Children's Repolated of Philadelphia 950080200-01C 21.000 Cancer Creatment Research 93.365 Children's Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.365 Children's Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.365 Children's Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.367 University Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.387 University Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.387 University Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.387 University Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.387 University Repolated of Philadelphia 9400270813 156 Cancer Creatment Research 93.388 Washington University 8500020 156 Cancer Creatment Research 93.388 Washington University WU-19-123WU-20-141 7,172 Lung Diseases Research 93.388 Washington University WU-19-123WU-20-141 7,172 Lung Diseases Research 93.388 University Michigan 96005482-008 158 Cancer Creatment Research 93.389 University of Michigan 96005482-008 158 Cancer Creatment Research 93.389 University of Research Prestitute ACRIEGO 947 Cancer Creatment Research 93.389 University of Research Prestitute ACRIEGO 947 Cancer Creatment Research 93.389 University of Texas Southwestern Medical Center 940021075 9600 Cancer Creatment Researc		93.310				
Nursing Research Sicke Cell Treatment Demonstration Program Sicke Cell Treatment Research Sicke Si			UAMS	52966		_
Sickle Call Treatment Demonstration Program \$3.365 Washington University WU-19-154 WU-20-194 62.965						_
Cancer Treatment Research			Washington University	WU-19-154 / WU-20-194		_
Cancer Treatment Research	·					_
Cancer Treatment Research	Cancer Treatment Research	93.395	Children's Hospital of Philadelphia	95002080220-xx	6,923	_
Total for Program						_
Cardovascular Diseases Research 93.399 Children's Hospital of Philadelphia UG1CA189955 692						
Cardiovascular Diseases Research 93.837 University of Rochester 416872/GR10484 7 13.363 Total for Program 13.363 Ling Diseases Research 93.838 Rutgers University 8299/1180 92.432 Ling Diseases Research 93.838 Rutgers University 8299/1180 92.432 Ling Diseases Research 93.838 Washington University W1.19-123/WU-20-141 7,172 Ling Diseases Research 93.838 University W1.19-123/WU-20-141 7,172 Ling Diseases Research 93.838 University W1.19-123/WU-20-141 9,172 Ling Diseases Research 93.838 University W1.19-123/WU-20-141 9,172 Ling Diseases Research 93.839 University W1.19-123/WU-20-141 9,172 Ling Diseases Research 93.839 University W1.19-123/WU-20-141 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172 9,172		93 399	Children's Hospital of Philadelphia	UG1CA189955		
Cardiovascular Diseases Research						_
Lung Diseases Research 93.838 Rutgers University 8299/1160 \$ 92.432 Lung Diseases Research 93.838 Washington University WU-19-123/WU-20-141 7,172 Lung Diseases Research 93.838 Washington University WU-19-123/WU-20-141 7,172 Lung Diseases Research 93.838 NTU Grossman PED-03-21 3,634.291 Lung Diseases Research 93.838 NTU Grossman PED-03-21 3,634.291 Lung Diseases Research 93.838 University of Pennsylvania 583403 41,011 Lung Diseases Research 93.838 University of Pennsylvania 583403 41,011 Lung Diseases Research 93.838 University of Michigan 40,03918 8,922 Lung Diseases Research 93.838 Regents of the UCSF 12795sc 60,944 Total for Program 12795sc 60,944 Blood Diseases and Resources Research 93.839 University of Alabama at Birmingham 0,00524452-008 28,446 Blood Diseases and Resources Research 93.839 University of Alabama at Birmingham 0,00524452-008 296,444 Blood Diseases and Resources Research 93.839 University of Alabama at Birmingham 0,00524452-008 2,008 2,008 Blood Diseases and Resources Research 93.839 University of Alabama at Birmingham 0,00524452-008 2,008 2,008 Blood Diseases and Resources Research 93.839 University of Piniadelphia 3,007,006 2,008 Blood Diseases and Resources Research 93.839 University of Texas Southwestern Medical Center GMO21075 2,400 Diabetes, Digestive, and Kidney Diseases Extramural Research 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 156,755 15					13,356	
Lung Diseases Research 93.838 Washington University WU-19-123/WII-20-141 7,172 Lung Diseases Research 93.838 CpR Research Corporation 20200582 (1,451) Lung Diseases Research 93.838 NU Grossman PED-03-21 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3,634,291 3	Total for Program				13,363	
Lung Diseaser Research	Lung Diseases Research					_
Luno Diseases Research 93.838 NU Grossman PED-02-21 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634 /291 3.634	Lung Diseases Research	93.838				=
Lung Diseases Research						3,305,243
Lung Diseases Research	Lung Diseases Research	93.838	University of Pennsylvania	583403	41,011	_
Lung Diseases Research 93.838 Regents of the UCSF 12795sc 60,944 Total for Program 3,844,268 3 Blood Diseases and Resources Research 93.839 University of Alabama at Birmingham 000524452-008 28,846 Blood Diseases and Resources Research 93.839 All Children's Research Institute ACR162-001 147 Blood Diseases and Resources Research 93.839 Children's Research Institute ACR162-001 147 Blood Diseases and Resources Research 93.839 Children's Research Institute 3201710624 703 Blood Diseases and Resources Research 93.839 University of Texas Southwestern Medical Center GMO21075 2,400 Total for Program 93.847 Total for Program 156,755 156,755	Lung Diseases Research					_
Blood Diseases and Resources Research 93.839 University of Alabama at Birmingham 000524452-008 28.846		93.838	Regents of the UCSF	12795sc		
Blood Diseases and Resources Research 93.839						3,305,243
Blood Diseases and Resources Research 93,839 298,444 298,444 703 703 703 703 703 704 704 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 705 7			University of Alabama at Birmingham All Children's Research Institute			_
Blood Diseases and Resources Research 93.839 University of Texas Southwestern Medical Center GMO21075 2,400 330,540 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Blood Diseases and Resources Research	93.839			298,444	_
Total for Program 330,540 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.847 156,755						=
Diabetes, Digestive, and Kidney Diseases Extramural Research 93.847 156,755		95.639	Oniversity or rexas Southwestern Medical Center	JIVIO2 1073		
	•					
			La Jolla Institute for Alleroy and Immunology	20108-02-111-342		2,600
Diabetes, Digestive, and Kidney Diseases Extramural Research 93.847 Univ. of Kansas Med Center Research Inst. ZAH00030 5,780	Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Univ. of Kansas Med Center Research Inst.	ZAH00030		_
Total for Program	Total for Program				207,863	2,600
Extramural Research Programs in the Neurosciences and Neurological Disorders 93.853 University of Washington UWSC7774 (10)	Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	UWSC7774		_

6

Schedule of Expenditures of Federal Awards

Year ended June 30, 2022

	Assistance Listing				Amounts passed
Federal grantor/pass-through grantor/program or cluster title	Number (ALN)	Pass-through entity	Pass-through entity identifying number	Expenditures recognized	through to subrecipients
Alleray and Infectious Diseases Research	93.855			648	
Allergy and Infectious Diseases Research	93.855	University of California San Diego	82054019	11.536	_
Alleroy and Infectious Diseases Research	93.855	University of California San Diego	77382527	34.721	_
Allergy and Infectious Diseases Research	93.855	University of California San Diego	78456631	70.507	_
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2004200724	571,939	_
Allerry and Infectious Diseases Research	93.855	Johns Hopkins University	N/A	430,379	_
Allergy and Infectious Diseases Research	93.855	University of Alabama at Birmingham	000522211-001	3,246	_
Allergy and Infectious Diseases Research	93.855			121,502	_
Allergy and Infectious Diseases Research	93.855	Duke University	234740	(1,867)	_
Allergy and Infectious Diseases Research	93.855	Cincinnati Children's Hospital Medical Ctr	309363	24,706	_
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute	3UM1AI109565-08	154,405	_
Allergy and Infectious Diseases Research	93.855			214,564	_
Allergy and Infectious Diseases Research	93.855			58,267	_
Allergy and Infectious Diseases Research	93.855			829	_
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	1983505	438	_
Allergy and Infectious Diseases Research	93.855	Regents of the University of New Mexico	3RJHS	37,578	_
Allergy and Infectious Diseases Research	93.855			162,995	
Total for Program				1,896,393	
Biomedical Research and Research Training	93.859			2,339,257	295,337
Biomedical Research and Research Training	93.859			2,756,866	381,977
Biomedical Research and Research Training	93.859			155,174	
Total for Program				5,251,297	677,314
Child Health and Human Development Extramural Research	93.865			47,909	_
Child Health and Human Development Extramural Research	93.865	Vanderbilt University	VUMC 54975	665	_
Child Health and Human Development Extramural Research	93.865			9,994	_
Child Health and Human Development Extramural Research	93.865	Children's Mercy Hospital	41606123	4,208	_
Child Health and Human Development Extramural Research	93.865			30,779	
Child Health and Human Development Extramural Research	93.865			620,637	124,795
Total for Program				714,192	124,795
Vision Research	93.867	Jaeb Center for Health Research, Inc.	N/A	(216)	_
Vision Research	93.867	Jaeb Center for Health Research, Inc.	N/A	1,691	_
Vision Research	93.867	Jaeb Center for Health Research, Inc.	UG1EY011751	3,638	
Total for Program				5,113	
Prime Contract #HHSN275201800003I	93.RD	Duke University	00000193	97,050	_
Prime Contract #HHSN2752018000031	93.RD	University of Pittsburgh	00002738	1,119	_
Prime Contract #HHSN2752010000031	93.RD	Duke University	226749	6,221	_
Prime Contract #HHSN2752010000031	93.RD	Duke University	218637	6,266	_
Prime Contract #HHSN172101600017C	93.RD	University of Alabama at Birmingham	000509729-003	1,858	_
Contract	93.RD	Children's Hospital of Philadelphia	AHOD1822	22,449	_
Prime contract #6132062D0002	93.RD	Consumer Product Safety Commission	9522	101,113	_
8U24OD024957	93.RD	UAMS	50164	44,561	_
Contract	93.RD	UAMS	N/A	1,496	_

7 (Continued)

Schedule of Expenditures of Federal Awards

Year ended June 30, 2022

Federal grantor/pass-through grantor/program or cluster title	ALN	Pass-through entity	Pass-through entity identifying number	Expenditures recognized	Amounts passed through to subrecipients
1UG3HL141736-01	93.RD	Boston Children's Hospital	4615527	\$ 7,476	_
Prime Contract #75D30119C05584	93.RD	Boston Children's Hospital	0001756163	10,501	_
KCNQ2 Channels Control Chemoreceptor	93.RD	University of Connecticut	N/A	18,485	_
Autism and Developmental Disabilities Monitoring Contract #75D30120C07725	93.RD 93.RD	UAMS Boston Children's Hospital	N/A N/A	14,657 5.834	_
Contract #75D30120C07725 Contract	93.RD 93.RD	Quadrant Children's Hospital	N/A N/A	5,834 72,460	_
Total U.S. Department of Health and Human Services	30.112	quadrant	N/A	14.949.234	4.109.952
Total Research and Development Cluster				24,736,775	4,393,616
				24,730,773	4,393,010
477 Cluster:					
U.S. Department of Health and Human Services:	00.575	Advances Department of the control of	NIA	040 400	
Child Care and Development Block Grant	93.575	Arkansas Department of Human Services	N/A	818,482	_
Other Programs:					
U.S. Department of Agriculture:					
Specialty Crop Block Grant	10.170	Arkansas Agriculture Department	AM190100XXXXG015	905	_
Child and Adult Care Food Program	10.558	Arkansas Department of Human Services	A233	19,082	
Total U.S. Department of Agriculture				19,987	
U.S. Department of Education:					
Special Education Grants to States (EARS Program)	84.027	Arkansas Department of Education	N/A	225,000	_
U.S. Department of Health and Human Services:					
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center of Houston	0011472A	20,158	_
COVID-19 Testing for the Uninsured	93.461	·		195,778	_
COVID-19 Provider Relief Fund *	93.498			19,567,980	_
Affordable Care Act Maternal, Infant and Early Childhood Home Visiting Program	93.505	Arkansas Department of Health	#4600046694	5,631,115	4,534,312
Foster Care_Title IV-E	93.658	Arkansas Department of Human Services	N/A	2,363	_
Maternal and Child Health Services Block Grant to the States	93.994	Arkansas Department of Health	#4600046719	32,800	
Total U.S. Department of Health and Human Services				25,450,194	4,534,312
Corporation for National and Community Service:					
AmeriCorps VISTA	94.013			3,291	_
Agency for International Development:					
USAID Foreign Assistance for Programs Overseas	98.001	Purdue University	F9000735402077	6,003	_
U.S. Department of Transportation:					
Child Passenger Safety Education Project	20.600	Arkansas State Police	M2CPS-2022-08-08-01	180.540	_
Drive Smart Challenge	20.600	Arkansas State Police	M8V-2022-11-11-01	133.144	_
Total U.S. Department of Transportation				313,684	
U.S. Department of Veteran Affairs	64.xx			13.555	
Total Expenditures of Federal Awards				\$ 51,586,971	8,927,928
Total Experiorities of Federal Awards				φ <u>51,000,971</u>	0,921,920

^{*} Denotes major program

See accompanying Independent Auditors' Report.

See accompanying notes to Schedules of Expenditures of Federal Awards and Expenditures of State of Arkansas Financial Assistance.

Schedule of Expenditures of State of Arkansas Financial Assistance

Year ended June 30, 2022

State grantor/pass-through grantor/program title	State award number	Pass-through entity identifying number		Revenue	Expenditures recognized
Direct Appropriations:					
Indigent Care Appropriation (1)	ACT #1005	N/A	\$	1,994,758	1,994,758
Intensive Care Nursery (1)	ACT #997	N/A		219,638	219,638
Children's Hospital Payments (1)	ACT #997	N/A		658,283	658,283
Helicopter Funding (1)	ACT #997	N/A		1,000,000	1,000,000
Burn Unit (1)	ACT #997	N/A		940,282	940,282
Arkansas Reproductive Health Monitoring System (1)	ACT #997	N/A		564,283	564,283
Child Health and Family Life Institute (1)	ACT #843	N/A		2,100,000	2,100,000
Division of Developmental Disabilities Services (CMS)	N/A	N/A		3,456	3,456
Division of Children and Family Services	N/A	N/A		224,490	224,490
Arkansas Attorney General	N/A	N/A		900	900
Passed through the Department of Education:					
HIPPY Arkansas Better Chance	ACT #1006	N/A		455,235	455,235
Passed through the Department of Finance and Administration:					
Baby Sharon	ACT #997	N/A		30,503	30,503
Passed through the Department of Health:					
Trauma Center	ACT #393	#4600046674		1,008,357	1,008,357
Burn Center	ACT #393	#4600046672		15,525	15,525
Infant Child Death Review	ACT #1818	#4600029163		108,176	108,176
Tobacco Prevention	ACT #50	#4600042612		303,882	303,882
Passed through the Department of Human Services:					
Foster Care – Title IV-E State	N/A	N/A		667	667
Passed through UAMS:					
Arkansas Biosciences Institute – CHART Programmatic Area Expenditures	ACT #194	N/A	_	1,668,852	1,085,800
Total State Awards			\$	11,297,287	10,714,235

⁽¹⁾ Remitted to Arkansas Medicaid, on behalf of Arkansas Children's Hospital, to be used as match for supplemental Medicaid payments.

See accompanying Independent Auditors' Report.

See accompanying notes to Schedules of Expenditures of Federal Awards and Expenditures of State of Arkansas Financial Assistance.

Notes to Schedules of Expenditures of Federal Awards and Expenditures of State of Arkansas Financial Assistance

June 30, 2022

(1) Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards summarizes the expenditures of Arkansas Children's under programs of the federal government for the year ended June 30, 2022. The accompanying Schedule of Expenditures of State of Arkansas Financial Assistance (collectively with the Schedule of Expenditures of Federal Awards, the Schedules) summarizes the expenditures of Arkansas Children's under programs of the state government for the year ended June 30, 2022. The information in the Schedule of Expenditures of Federal Awards is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedules present only a selected portion of the operations of Arkansas Children's, they are not intended to, and do not, present the financial position, changes in net assets or cash flows of Arkansas Children's.

For purposes of the Schedules, federal awards include all grants, contracts, and similar agreements entered into directly between Arkansas Children's and agencies and departments of the federal government and all subawards to Arkansas Children's by nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

(2) Summary of Significant Accounting Policies

For the purpose of the Schedules, expenditures of federal and state award programs are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The 10% de minimis cost rate (as covered in 2 CFR Part 200.414) was not used. Instead a federally negotiated indirect cost rate was used during the year.

(3) Governmental Assistance

In addition to amounts listed on the Schedules, Arkansas Children's reported \$481,300,106 of other governmental assistance, in the form of Medicaid reimbursements and Children's Hospital Graduate Medical Education payments during the fiscal year ended June 30, 2022, which are not subject to the audit requirements as defined in the Uniform Guidance.

(4) Provider Relief Fund

As required by the granting agency, the Provider Relief Fund (PRF) amounts presented in the schedule of expenditures of federal awards represent lost revenues and expenses as reported to the U.S. Department of Health and Human Services for the PRF portal reporting time periods of January 1, 2022 to March 31, 2022 and July 1, 2022 to September 30, 2022.

ARKANSAS CHILDREN'S HOSPITAL

Schedule of Units of Service Year ended June 30, 2022 (Unaudited)

Child and adult care food program Breakfast Lunch Supplements Number of meals served: 1,610 July 1,646 1,667 1,340 August 1,324 1,324 September 1,610 1,649 1,661 October 1,474 1,540 1,536 November 1,442 1,480 1,487 December 1,368 1,392 1,405 1,170 1,153 January 1,134 February 1,310 1,373 1,337 March 1,709 1,790 1,757 April 1,595 1,659 1,637 May 1,762 1,812 1,795 June 1,765 1,863 1,828 Total number of meals served 18,139 18,735 18,530

See accompanying Independent Auditors' Report.

Schedule of Findings and Questioned Costs June 30, 2022

(1) Summary of the Auditors' Results

Audit of the Financial Statements

- (a) Type of auditors' report issued on whether the financial statements were prepared in accordance with U.S. generally accepted accounting principles unmodified opinion
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the financial statements:
 - Material weaknesses identified? No
 - Significant deficiencies identified? None reported
- (c) Noncompliance material to financial statements noted? No

Audit of Federal Awards

- (d) Internal control deficiencies over major federal program compliance disclosed by the audit of federal awards:
 - Material weaknesses identified? No
 - Significant deficiency identified? None reported
- (e) Type of auditors' report issued on compliance for major programs unmodified opinion

Name of major federal program or cluster	ALN	
COVID-19 Provider Relief Fund	93.498	

- (f) Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a) No
- (g) Dollar threshold used to distinguish between type A and type B programs \$1,547,609
- (h) Audit qualified as low-risk auditee? Yes
- (2) Findings Relating to the Financial Statements Reported in Accordance with Government Auditing Standards

None

(3) Findings and Questioned Costs Relating to Federal Rewards

None